首页ATBPF • OTCMKTS
add
Antibe Therapeutics Ord Shs
市场资讯
财务信息
损益表
收入
净收入
| (CAD) | 2023年12月info | 年同比变化 |
|---|---|---|
收入 | — | — |
经营支出 | 459.60万 | -1.42% |
净收入 | -421.30万 | 2.39% |
净利润率 | — | — |
每股收益 | -0.08 | 0.50% |
息税折旧摊销前利润 | — | — |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (CAD) | 2023年12月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 2490.60万 | -41.20% |
总资产 | 5636.20万 | -23.56% |
负债总额 | 3042.50万 | -0.13% |
权益总额 | 2593.70万 | — |
发行在外的股份 | 5266.54万 | — |
市净率 | 0.44 | — |
资产回报率 | -19.71% | — |
资本回报率 | -41.30% | — |
现金流
现金净变动
| (CAD) | 2023年12月info | 年同比变化 |
|---|---|---|
净收入 | -421.30万 | 2.39% |
来自运营的现金 | -384.50万 | -6.66% |
投资现金 | 1104.10万 | 1,975.38% |
融资现金 | — | — |
现金净变动 | 719.60万 | 334.09% |
自由现金流 | -246.88万 | -2,419.13% |
简介
Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.
On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug Otenaproxesul.
On March 29, 2021, the drug's Investigational New Drug application was cleared by the US Food and Drug Administration, allowing for human trials.
In May 2024 the company went bankrupt and its stock was delisted from the Toronto Stock Exchange. Wikipedia
成立时间
2009
员工数量
11
